Repository logo
 
Publication

Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future

2021Journal article Open access
Simple item page
dc.contributor.authorDanne, T
dc.contributor.authorLimbert, C
dc.contributor.authorPuig Domingo, M
dc.contributor.authorDel Prato, S
dc.contributor.authorRenard, E
dc.contributor.authorChoudhary, P
dc.contributor.authorSeibold, A
dc.date.accessioned2022-03-09T11:53:50Z
dc.date.available2022-03-09T11:53:50Z
dc.date.issued2021
dc.description.abstractPeople with diabetes are at greater risk for negative outcomes from COVID-19. Though this risk is multifactorial, poor glycaemic control before and during admission to hospital for COVID-19 is likely to contribute to the increased risk. The COVID-19 pandemic and restrictions on mobility and interaction can also be expected to impact on daily glucose management of people with diabetes. Telemonitoring of glucose metrics has been widely used during the pandemic in people with diabetes, including adults and children with T1D, allowing an exploration of the impact of COVID-19 inside and outside the hospital setting on glycaemic control. To date, 27 studies including 69,294 individuals with T1D have reported the effect of glycaemic control during the COVID-19 pandemic. Despite restricted access to diabetes clinics, glycaemic control has not deteriorated for 25/27 cohorts and improved in 23/27 study groups. Significantly, time in range (TIR) 70-180 mg/dL (3.9-10 mmol/L) increased across 19/27 cohorts with a median 3.3% (- 6.0% to 11.2%) change. Thirty per cent of the cohorts with TIR data reported an average clinically significant TIR improvement of 5% or more, possibly as a consequence of more accurate glucose monitoring and improved connectivity through telemedicine. Periodic consultations using telemedicine enables care of people with diabetes while limiting the need for in-person attendance at diabetes clinics. Reports that sustained hyperglycaemia and early-stage diabetic ketoacidosis may go untreated because of the lockdown and concerns about potential exposure to the risk of infection argue for wider access to glucose telemonitoring. Therefore, in this paper we have critically reviewed reports concerning use of telemonitoring in the acute hospitalized setting as well as during daily diabetes management. Furthermore, we discuss the indications and implications of adopting telemonitoring and telemedicine in the present challenging time, as well as their potential for the future.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationDiabetes Ther . 2021 Sep;12(9):2289-2310.pt_PT
dc.identifier.doi10.1007/s13300-021-01114-xpt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3993
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringerlinkpt_PT
dc.subjectAmbulatory glucose profilept_PT
dc.subjectCOVID-19pt_PT
dc.subjectContinuous glucose monitoringpt_PT
dc.subjectDiabetespt_PT
dc.subjectInsulin pumpspt_PT
dc.subjectMortalitypt_PT
dc.subjectMortalitypt_PT
dc.subjectTelemedicinept_PT
dc.subjectTelemonitoringpt_PT
dc.subjectVirtual carept_PT
dc.subjectHDE END PEDpt_PT
dc.titleTelemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Futurept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2310pt_PT
oaire.citation.issue9pt_PT
oaire.citation.startPage2289pt_PT
oaire.citation.volume12pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Diabetes Ther 2021_2289.pdf
Size:
563.29 KB
Format:
Adobe Portable Document Format
Download

Collections

END PED - Artigos